German antitrust regulator clears Esperion acquisition by ArchiMed

Esperion Therapeutics, Inc.

Bundeskartellamt cleared the merger effective June 2, 2026, as notified June 8.
Completion still requires HSR waiting period expiration and stockholder approval.
Special stockholder meeting to vote on merger scheduled for July 8, 2026, at 8:00 a.m. ET.
Merger announced May 1, 2026; Esperion to become wholly owned by ArchiMed affiliate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.